A 12-month post-treatment threshold effectively differentiates early from late progression in CLL, impacting survival outcomes significantly. Early progression within 12 months post-treatment ...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie, in collaboration with Hoffmann-La Roche and the German CLL Study Group, has completed a Phase III clinical trial titled ‘A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results